Various novel therapies for MS are under investigation (Table 2). Alemtuzumab has an approximate molecular weight of 150 kD and is of the IgG1 subclass. It is delivered in isotonic (pH 6.8–7.4 ...

The phase 2 study's results are certainly unprecedented in MS. But whether Campath (alemtuzumab), a monoclonal antibody (mAb) already approved to treat leukemia, actually 'reverses' MS ...

Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on lymphocytes and monocytes. Pulsed administration causes prolonged T-cell depletion and has been shown to be ...

There is growing clinical evidence that aHSCT can treat RRMS more effectively than DMTs. However, as most data is registry-based and previous trials did not directly compare aHSCT with the most ...